Women with Long COVID-19 syndrome are more symptomatic than men

A new study found that females with Long COVID-19 syndrome were more symptomatic than males. Females were statistically significantly more likely to experience difficulty swallowing, fatigue, chest pain, and palpitations at long-term follow-up, according to a study published in the peer-reviewed Journal of Women's Health.

Long-COVID-syndrome is defined as persistent symptoms extending beyond 12 weeks after the initial symptoms of acute infection. In this study by Giovanna Pelà, MD, PhD, University of Parma, and University-Hospital of Parma, and coauthors, 91% of patients evaluated at follow-up (mean, 5 months) continued to experience COVID-19 symptoms. Breathlessness was the most common symptoms of long COVID-19, followed by fatigue. Females were more symptomatic than males (97% vs. 84%).

"Long-term longitudinal studies are needed to fully understand the sex-related pathophysiology of the symptoms and the effects of pharmacological treatment related to Long COVID-19; these studies will be crucial to understanding the natural trajectory of Long COVID-19 in order to implement targeted treatment strategies and to prevent bias in treating males and females," concluded the investigators.

While women have a lower mortality rate than men during the acute phase of COVID, this study indicates that women have a greater likelihood of experiencing Long Covid syndrome."

Susan G. Kornstein, MD, Journal of Women's Health Editor-in-Chief, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA

Source:
Journal reference:

Pelà, G., et al. (2022) Sex-Related Differences in Long-COVID-19 Syndrome. Journal of Women's Health. doi.org/10.1089/jwh.2021.0411.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients